Abstract: Magnesium-aluminum layered double hydroxides intercalated with antitumor drug etoposide (VP16) were prepared for the first time using a two-step procedure. The X-ray powder diffraction data suggested the intercalation of VP16 into layers with the increased basal spacing from 0.84-1.18 nm was successful. Then, it was characterized by X-ray powder diffraction, Fourier transform infrared spectroscopy, thermogravimetry and differential thermal analysis, and transmission electron microscopy. The prepared nanoparticles, VP16-LDH, showed an average diameter of 62.5 nm with a zeta potential of 20.5 mV. Evaluation of the buffering effect of VP16-LDH indicated that the nanohybrids were ideal for administration of the drugs that treat human stomach irritation. The loading amount of intercalated VP16 was 21.94% and possessed a profile of sustained release. The mechanism of VP16-LDH release in the phosphate buffered saline solution at pH 7.4 is likely controlled by the diffusion of VP16 anions from inside to the surface of LDH particles. The in vitro cytotoxicity and antitumor assays indicated that VP16-LDH hybrids were less toxic to GES-1 cells while exhibiting better antitumor efficacy on MKN45 and SGC-7901 cells. These results imply that VP16-LDH is a potential antitumor drug for a broad range of gastric cancer therapeutic applications.
Introduction
Etoposide (VP16) (Figure 1 ) is a semisynthetic derivative of podophyllotoxin, which acts by inhibition of one of the most abundant nuclear proteins, deoxyribonucleic acid (DNA) topoisomerase 2. Etoposide is cell cycle-specific and leads to an accumulation of cells in G2/M. 1 Thus, it has a significant effect on a large range of carcinomas, particularly gastric cancer cells, small cell lung carcinoma, germ cell tumors, hematologic malignancies, and childhood malignancies. However, the inhibition of enzymes can only be saturated at high drug concentrations with prolonged exposure, which would lead to greater cytotoxicity. [2] [3] [4] [5] Moreover, deficiencies such as poor water solubility, metabolic inactivation, drug resistance, myelosuppression, and poor bioavailability have limited their scopes of applications. [6] [7] [8] As a result, a drug delivery system may represent an attractive prospect for overcoming these pharmaceutical limitations and improving their clinical application.
Layered double hydroxides (LDHs) are a family of anionic clay materials, exemplified by the natural mineral hydrotalcite [Mg 6 Al 2 (OH) 16 ) stands for the layer charge density of LDH. 9, 10 In recent years, LDHs have been found to have promising use in biomedicine. Their low cost, good biocompatibility, low toxicity to mammalian cells, controlled-release system, and ability to provide full protection for loaded drugs make them suitable candidates for drug delivery systems. 11, 12 Many LDH compounds intercalated with beneficial organic anions, such as deoxyribonucleic acid DNA, [13] [14] [15] [16] amino acids, [17] [18] [19] [20] [21] [22] anionic polymers, 23 pesticides, 24, 25 and drugs, [26] [27] [28] [29] [30] have been prepared successfully. Special interests have focused on exploring the possibilities of using LDH drug delivery systems to deliver antiinflammatory drugs, 31 anticoagulants like heparin, 32 or anticancer drugs. 33, 34 These studies involve some basic issues, including the intercalation (loading) of drugs or biomolecules into the LDH interlayer, the release behaviors of drugs or biomolecules from the LDH interlayer under different physiological conditions, the toxicity of LDH materials to cells, the cellular uptake of LDH nanoparticles, and cellular drug delivery tests. Furthermore, this drug delivery system can be modified to target specific cells or organs, thereby expanding its application range.
The aim of this paper was to intercalate the antitumor drug VP16 into the LDH interlayer and characterize the resultant nanohybrids with a set of tests. The buffer effect and release behavior were also evaluated. The in vitro cell cytotoxicity and antitumor assays showed VP16-LDH to be less toxic to GES-1 cells while providing better antitumor efficacy on MKN45 and SGC-7901 cells.
Materials and methods Materials
Etoposide was a kind gift from the University of Science and Technology of China. Mg(NO 3 ) 2 ⋅ 6H 2 O, Al(NO 3 ) 3 ⋅ 9H 2 O, and tyrosine (Tyr) were purchased from the China National Medicine Group, Shanghai Chemical Reagents Company (Shanghai, People's Republic of China), and were used without further purification. Roswell Park Memorial Institute-1640, fetal calf serum, penicillin G, streptomycin, and trypsinase were obtained from Gibco-BRL (Life Technologies Corporation, Grand Island, NY, USA). Dimethyl sulfoxide and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] were purchased from Sigma-Aldrich (St Louis, MO, USA). Deionized water was decarbonated by boiling before use in all applications.
Preparation of nanohybrids
The nanohybrids were prepared using a two-step procedure, which we described previously. 28, 34 First, Tyr-LDH was prepared via the coprecipitation method under a nitrogen (N 2 ) atmosphere, as is conventional to minimize or avoid contamination by atmospheric CO 2 .
35 A mixed solution of 1 M Mg (NO 3 ) 2 ⋅ 6H 2 O and Al(NO 3 ) 3 ⋅ 9H 2 O (Mg:Al ratio of 3:1) was added dropwise to an aqueous solution of 1 M Tyr while vigorously stirring under a nitrogen atmosphere at room temperature. The pH of the resultant suspension was then adjusted to 10.0 ± 0.2 by adding 1 M NaOH solution dropwise while vigorously stirring at 80°C for 5 hours in a nitrogenfilled environment. This resulted in the formation of Tyr-LDH precipitates, which were then harvested by filtering, vacuum dried overnight, and used for subsequent investigations.
Second, VP16-LDH nanohybrids were prepared via ion exchange. The freshly prepared Tyr-LDH suspension was added to a 0.1 M VP16 solution (pH previously adjusted to 12 using NaOH). The mixture was magnetically stirred continuously under a nitrogen atmosphere at 80°C for 5 hours. The resultant slurry was then filtered, washed thoroughly with decarbonated water, and dried overnight. The product was denoted as VP16-LDH. 
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Japan) using CuKa radiation (λ = 0.154060 nm, 40 kV, 40 mA, step of 0.0330°). The average particle size (z-average size) and size distribution were measured using photon correlation spectroscopy (LS230, Beckman Coulter Inc, Brea, CA, USA) at 25°C under a fixed angle of 90° in disposable polystyrene cuvettes. The measurements were recorded using a He-Ne laser of 633 nm. Zeta potential distribution of the nanoparticles was analyzed by Nano ZS (Malvern Instruments, Malvern, UK). Fourier transform infrared spectroscopy were obtained on a Bruker Vector 22 spectrophotometer in the range of 4000-500 cm -1 using the standard KBr disk method (sample/ KBr = 1/100) (Bruker AXS, Inc., Billerica, MA, USA). Thermogravimetry (TG) and differential thermal analysis (DTA) were carried out on a Perkin-Elmer Pyris 1 TG/DTA instrument with a heating rate of 10°C/minute in flowing air (PerkinElmer, Waltham, MA, USA). Transmission electron micrographs were taken using a JEOL 1230 transmission electron microscope (TEM) (JOEL, Tokyo, Japan). Ultraviolet-visible (UV-VIS) absorption spectra were measured on a Cary 50 spectrophotometer (Varian, VIC, Australia).
Evaluation of the buffer effect
The buffer effect of VP16-LDH was evaluated by monitoring the pH changes in each suspension with the addition of 1 M HCl aqueous solution. A typical experiment was performed using a 100 mg sample in 10 mL of deionized distilled water. The flask was stirred continuously at 37°C. Aqueous HCl solution was subsequently added to each suspension until pH stabilized at an approximate value of 1.
In vitro VP16 release test from VP16-LDh
To determine the amount of VP16 loaded into the LDH, a standard weight of the nanohybrids and 5 mL of 1 M HCl were placed in a 10 mL flask. The solution was stirred until LDH layers were completely dissolved and subsequently analyzed with a UV-VIS spectrophotometer against a series of standards prepared using the same method; the concentration of VP16 was determined by monitoring the absorbance at 285 nm and calculated according to an obtained standard curve of VP16 (A = 0.0113C + 0.0008, r = 0.9988). The drug loading was calculated as follows:
The VP16 release test was performed in phosphate buffered saline solutions (0.02 M) of pH 7.4 and 4.6 containing 0.02 g of VP16-LDH while gently shaking at a constant temperature of 37°C. Aliquots (2 mL) were withdrawn at desired time intervals and filtered through a 0.45 µm syringe filter. The accumulated amount of VP16 released was determined by UV absorption at 285 nm. Four dissolution-diffusion kinetic models were used to fit the in vitro VP16-LDH release profiles. [36] [37] [38] [39] [40] The zero-order model:
The first-order model:
The parabolic diffusion model:
The modified Freundlich model:
The zero-and first-order models are normally used to describe dissolution phenomena. The parabolic diffusion model expresses the diffusion controlled-release process. The modified Freundlich model explains diffusion behavior via ion exchange. In these equations, M 0 and M t are the amount of VP16 in the LDH hybrids at release time 0 and t, respectively, and k is the corresponding release rate constant. 40 
In vitro cytotoxicity and antitumor effect of VP16-LDh
Human gastric epithelial cell line (GES-1) and human gastric cancer cell lines (MKN45 and SGC-7901) were used in this study. Cells were routinely cultured at 37°C in 5% CO 2 atmosphere in the flasks containing 10 mL of Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 µg/mL streptomycin. At 80%-90% confluence, cells were disassociated using trypsin-EDTA (Ethylene Diamine Tetraacetic Acid) and plated at a density of approximate 2 × 10 4 cells per well in a 96-well plate. The number of viable cells was determined by MTT assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. After incubation at 37°C in a 5% CO 2 humid atmosphere for 24 hours, triplicate wells were treated with VP16, VP16-LDH, and LDH of various concentrations (5 µg/mL, 10 µg/mL, 20 µg/mL, and 40 µg/ mL), and incubation was continued as indicated above for 4 hours. For the LDH-treated wells, the amount of LDH was adjusted to be equal to that of VP16-LDH-treated wells. Subsequently, each well was incubated with 20 µL (5 mg/mL) of MTT dye solution for 4 hours at 37°C. Results and discussion XRD analysis XRD patterns of LDH and the VP16-LDH nanohybrid are shown in Figure 2 , and the basal spacing calculated from the XRD patterns is shown in Table 1 . As shown in Figure 2 , pristine LDH showed a typical XRD pattern for LDH-NO 3 with basal spacing of 0.84 nm. Intercalation of drugs led to a significant increase in the interlayer space. As shown in Figure 2B , the reflection peaks in the pattern for VP16-LDH shift to lower angles and become weaker. This suggested that the successful intercalation of VP16 anions increased the basal spacing from 0.84-1.18 nm. Assuming a thickness of 0.48 nm for the brucite-like layer of LDH, 41 the gallery height in VP16-LDH became 0.70 nm, which is shorter than the molecular length of VP16 (≈1.34 nm). As shown in Figure 3 , based on the calculated gallery height, it can be deduced that the VP16 molecules were arranged in a tilted longitudinal monolayer, with tilting angles of approximately 58°. As shown in Table 1 , the amount of VP16 intercalated into the LDH was calculated using a UV-VIS spectrophotometer and its drug loading was about 21.94% (w/w).
Fourier transform infrared (FTIR) and thermal stability analysis
The intercalation of VP16 into LDH interlayers was also suggested by infrared spectroscopy. As shown in Figure 4A , the pristine LDH-NO 3 spectrum contained some peaks that commonly appear in magnesium-aluminum layered double hydroxides spectra. 18, 42 The broad absorption band around 3400 cm -1 was due to the stretching of O-H groups of both the hydroxide layer and interlayer water. The strong absorption band at 1384 cm -1 was due to stretching vibration of NO 3 -. In the low-frequency region, the bands at 809, 601, and 436 cm -1 were ascribed to the lattice vibration modes, specifically to M-O and O-M-O vibrations. As shown in Figure 4B and C, in the infrared spectrum of VP16 and VP16-LDH, the characteristic peaks around the absorption bands at 1486 cm -1 were due to the stretching vibrations of C=C in the backbone of the aromatic phenyl ring. Moreover, other VP16 absorption bands at 1249 and 1105 cm -1 observed in VP16-LDH were due to C-H vibration. Anionic exchange reaction resulted in the NO 3 -band at 1384 cm -1 becoming weaker, confirming that the interlayer NO 3 -ions were partly Degrees two theta (2θ) The TG/DTA curves of VP16-LDH nanohybrids are depicted in Figure 5 . The sample shows two noticeable weight loss stages. The first stage occurred at approximately 100°C-200°C due to the removal of absorbed water molecules and interlayer crystal water, overlapping with trace dehydroxylation of the LDH layer. The following mass loss at around 300°C-400°C is attributed to dehydroxylation of the hydroxide layer and thermal degradation of intercalated VP16 molecules. The temperature was higher than the decomposition temperature of VP16, which demonstrated that the thermal stability of intercalated VP16 molecule was enhanced. Furthermore, the major weight loss of VP16-LDH in temperatures ranging from 300°C-400°C was approximately 24.01%, which is similar to the loading amount of VP16 measured by UV-VIS spectroscopy.
26,27
Particle size distribution and TEM examination
The particle size and distribution dynamics of VP16-LDH were investigated by photon correlation spectroscopy. The nanoparticles of LDH and VP16-LDH were narrowly distributed with a nominal hydrodynamic diameter of 57.4 nm ( Figure 6A ) and 62.5 nm ( Figure 6C ), respectively; the zeta potentials were 35.3 mV ( Figure 6B ) and 20.5 mV (Figure 6D ), respectively. 
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TEM samples were prepared by adding 300 mL of LDH slurry to 15 mL of deionized water followed by probe sonication of the solution for 2 minutes. A drop of the solution was then placed on a holey carbon copper grid and air dried. As shown in Figure 7 , magnesium-aluminum layered double hydroxides were observed as compact, nonporous crystallites with a hexagonal platelike shape and a diameter of approximately 50 nm. When the VP16 intercalated into the inorganic host, the shape of the nanohybrid changed from regular hexagon to ellipse, and the crystal size increased, which was in accordance with the results of photon correlation spectroscopy.
Buffer effect of VP16-LDh
Gastric fluids were mimicked to study the buffer effect of VP16-LDH nanohybrids by monitoring the changes in pH values with the addition of 1 M HCl. 43 Figure 8 depicts the Figure 8 , the pH response of VP16 did not support a buffering property when pH value changed. However, VP16-LDH exhibited major buffering capacity when pH value was around 4. The neutralizing and buffering capabilities of VP16-LDH nanohybrids may come from the hydroxyl groups in its layers, and this function verifies LDH's effective role of antacid, which is also described in our previous study. 26, 27, 44 A three-phase release process can be observed. At the first stage with additive of HCl, the exfoliation of LDH particles was made by HCl to induce the integrity of the coating layer destroyed, which resulted in sharp decrement of solution pH from about 9.5-5.5. At the second stage, the pH of medium solution kept around 4, which was dependent on the neutralizing and buffering capabilities of VP16-LDH. At the last stage, the pH of medium solution was cut down and got to be 1 as the LDH nanoparticles were consumed by HCl. It may serve as an indicator that the LDH has begun dissolving; releasing VP16 through the removal of inorganic hosts under acidic conditions. 45 Thus, LDH may be an ideal antacid to prompt available VP16 diffusion in simulated gastric fluid.
In vitro drug release of VP16-LDh
The release properties of the VP16 from VP16-LDH were investigated by adding the intercalated compound to a sample of simulated gastrointestinal (pH 4.6) and blood fluids (pH 7.4). Figure 9 shows the release profiles of VP16-LDH nanohybrids and physically mixed powder (VP16 and LDH) in solutions at pH 4.6 and 7.4. VP16 released from VP16-LDH nanohybrids at pH 4.6 and 7.4 showed a burst release during the first 20 minutes, which can be attributed to the release of the VP16 that adsorbed onto the surface of LDH particles. Subsequently, a slower release behavior was observed, which may be due to an ion-exchange process between the intercalated anions in the interlayer and phosphate anions in the buffer. 46 At pH 7.4, the release of VP16-LDH was persistent and gradual, with released percentages of 51%, 74%, and 79% after 20, 150, and 390 minutes, respectively. As for the physical mixtures of VP16 and LDH, the release rate reached 85% immediately after 20 minutes, due to weak electrostatic interaction between VP16 molecules and the LDH surface. Thereafter, a slow decline of VP16 was observed with about 80% VP16 left in solution after 390 minutes, which may be attributed to the intercalation of VP16 into LDH. Such intercalation has been previously reported while observing the release of other drugs from a physical mixture. 32 Therefore, it can be concluded that VP16-LDH shows an obvious sustained release profile. This nanomaterial could help increase the practical delivery of VP16.
Four types of dissolution-diffusion kinetic models (zero-order, first-order, parabolic diffusion, and modified 
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Freundlich model) were used in an attempt to explain the mechanism of release. The corresponding linear correlation coefficients (R 2 ) were calculated ( Table 2) . At pH 7.4, the zero-and first-order models were not suitable to explain the whole release pattern of VP16-LDH, as evidenced by their small linear correlation coefficients with R 2 = 0.4225 and 0.5931 (Figure 10 ). The release of VP16-LDH followed the other two models much better, with R 2 = 0.9697 and 0.9230 for the parabolic diffusion and modified Freundlich models, respectively. The parabolic diffusion model describes intraparticle diffusion or surface diffusion, whereas the modified Freundlich model describes heterogeneous diffusion from flat surfaces via ion exchange. Thus, the drug release may be a coeffect, and a possible mechanism for VP16 release involves both intraparticle diffusion and surface diffusion, with either one being the main contributor. 44 At pH 4.6 (Figure 11 ), the zero-and first-order models were also not suitable for the release pattern with the R 2 = 0.6624 and 0.8345; however, the parabolic diffusion model was the best fit model for the release of VP16 (R 2 = 0.98). This suggests that the release from VP16-LDH is controlled by the diffusion of VP16 anions from inside to the surface of the LDH particles. In vitro cytotoxicity and antitumor effect of VP16-LDh Figure 12A shows the effect of VP16, LDH, and VP16-LDH on the proliferation of GES-1 cells at various VP16 concentrations. The cytotoxicity of VP16 and VP16-LDH to GES-1 cells increased with increasing dose of VP16, whereas pristine LDH had no significant cytotoxic effect. VP16-LDH has no obvious toxicity to GES-1 cells compared with free VP16 of the same concentration. Thus, LDH, as carriers of VP16, can effectively reduce the cytotoxicity of VP16 to normal cells. As shown in Figure 12B and C, VP16 and VP16-LDH suppressed the proliferation of tumor cells MKN45 and SGC-7901, whereas LDH by itself exerted no significant effect. Moreover, VP16-LDH had higher tumor suppression efficiency than VP16 alone at various concentrations. These results indicate that VP16-LDH may be more effective in cancer treatment than VP16 alone. This may be because VP16 in the hybrid system can reach tumor cell membranes before decomposing, because the VP16 molecules are stabilized when they are entrapped in LDH. Additionally, Choy et al 47 reported that the use of LDH nanoparticles as delivery vectors can improve the cellular uptake of biomolecules.
When LDH-drug particles are adhered to the cell membrane surface, some are internalized into the cell. The possible pathway for such nanohybrids to be internalized into cells is phagocytosis or endocytosis. 11 Some studies have shown that particles with diameters less than 200 nm are small enough to avoid nonselective uptake by macrophages of the reticuloendothelial system, and are more effective when they accumulate at the tumor site via the enhanced permeability and retention effect upon circulation in the blood vessels, [48] [49] [50] because tumor vessels are often dilated and fenestrated with an average pore size of less than 1 µm compared with normal tissue due to rapid formation of vessels that must serve the fast-growing tumor, 51 while normal tissues contain capillaries with tight junctions that are less permeable to nanosized particles. Therefore, VP16-LDH nanohybrids may be readily taken up by tumor cells and could thus permeate the tumor cell membrane much more effectively. 41, 52 These results suggest that LDH can be used as an excellent inorganic carrier for an advanced biocompatible drug delivery system, and VP16-LDH is a potential antitumor drug for a broad range of gastric cancer therapeutic applications. The in vivo delivery of VP16-LDH in an animal model will be performed in the future study.
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Conclusion
We successfully synthesized and characterized druginorganic nanohybrids, specifically constructs consisting of LDHs intercalated with VP16. The prepared nanoparticles contained an average diameter of 62.5 nm with a zeta potential of 20.5 mV. Evaluation of the buffering effect of VP16-LDH indicated that VP16-LDH possessed a good buffer effect in low pH media. The loading amount of intercalated VP16 was 21.94% and showed a profile of sustained release making a promising candidate for controlled drug release applications. The cytotoxicity and antitumor tests showed that VP16-LDH nanoparticles exhibited low toxicity to normal GES-1 cells and better antitumor efficacy on MKN45 and SGC-7901 cells. In summary, LDH may be an excellent inorganic carrier of VP16, and VP16-LDH shows great potential as an antitumor therapy. The promising results encourage us to perform further in vivo delivery in an animal model in the future. 
